In patients requiring chronic systemic corticosteroid therapy, the threshold for efficacy is unclear due to the suppressive effects of corticosteroids on blood eosinphil counts, yet mepolizumab has been shown to reduce or eliminate the need for systemic corticosteroid therapy.